Mizuho Securities reiterated a Neutral rating on Sucampo Pharmaceuticals (NASDAQ: SCMP), and raised the price target to $16.00 (from $13.00), following the company's 3Q earnings report. SCMP reported 3Q:16 revenue of $57.9M and $0.28 in EPS vs. consensus of $51.3M and $0.27. Management raised its 2016 revenue guidance to $220-$225M (from $195-$205M) and EPS of $1.20-$1.25 (from $0.97-$1.07).

Analyst Irina Koffler "We realize we missed the big move in the stock after a strong 3Q:16. However we see little momentum from here. We reiterate our Neutral rating and raise PT to $16 from $13."

For an analyst ratings summary and ratings history on Sucampo Pharmaceuticals click here. For more ratings news on Sucampo Pharmaceuticals click here.

Shares of Sucampo Pharmaceuticals closed at $15.20 yesterday.